EU/3/13/1109

About

On 12 March 2013, orphan designation (EU/3/13/1109) was granted by the European Commission to Eli Lilly Nederland B.V., the Netherlands, for 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-quinoline-6-carboxamide monohydrate for the treatment of hepatocellular carcinoma.

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in June 2019 on request of the Sponsor.

Key facts

Active substance
4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-quinoline-6-carboxamide monohydrate
Disease / condition
Treatment of hepatocellular carcinoma
Date of first decision
12/03/2013
Outcome
Withdrawn
EU designation number
EU/3/13/1109

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Eli Lilly Nederland B.V.
Papendorpseweg 83
Utrecht 3528 BJ
The Netherlands
Tel. +31 3060 25800
E-mail: eu_orphan@lilly.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating